Table 3.

All the patients in our center received LT after bridging/downstaging with immunotherapy.

Characteristics	LT after immunotherapy (n=24)
ICI molecules
Pembrolizumab	12 (50.0%)
Camrelizumab	7 (29.2%)
Tislelizumab	4 (16.7%)
Nivolumab	1 (4.1%)
Combination with lenvatinib	20 (83.3%)
Treatment cycles	3 (1–5)
Washout period (Day)	69.5 (18–206)
Rejection	3 (12.5%)
Recurrence	6 (25.0%)
Death	3 (12.5%)

Data are n (%) or median (Range).

ICI, immune checkpoint inhibitors; LRT, loco-regional therapy.